Pharmacological interventions in the treatment of the acute effects of cannabis: A systematic review of literature

Harm Reduction Journal

Volumn 9, Issue , 2012, Pages

  Crippa, José A S ^a   Derenusson, Guilherme N ^a   Chagas, Marcos H N ^a   Atakan, Zerrin ^b   Martín Santos, Rocio ^c,d   Zuardi, Antonio W ^a   Hallak, Jaime E C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^d INCT Translational Medicine ^*  (Brazil)

Author keywords

Acute effects; Anxiety; Cannabis; Intoxication; Pharmacological treatment; Psychosis

Indexed keywords

ANTIARRHYTHMIC AGENT; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANNABIDIOL; CANNABIS; NEUROLEPTIC AGENT; PROPRANOLOL; RIMONABANT;

ACUTE TOXICITY; ANXIETY; CANNABIS ADDICTION; CLINICAL TRIAL (TOPIC); COGNITION; HUMAN; PSYCHOSIS; REVIEW; SYSTEMATIC REVIEW;

EID: 84856078781     PISSN: None     EISSN: 14777517     Source Type: Journal    
DOI: 10.1186/1477-7517-9-7     Document Type: Review

References (55)

1. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964, 86:1646.
2. Diehl A, Cordeiro DC, Laranjeira R. Cannabis abuse in patients with psychiatric disorders: an update to old evidence. Rev Bras Psiquiatr 2010, 32(Suppl 1):S41-5.
3. ElSohly MA, Ross SA, Mehmedic Z, Arafat R, Yi B, Banahan BF. Potency trends of delta9-THC and other cannabinoids in confiscated marijuana from 1980-1997. J Forensic Sci 2000, 45:24-30.
4. National Center for the Development of Natural Products Quarterly Report Potency Monitoring Project M, 2003-August 8, 2003: NIDA Marijuana Project. 2003, University, Miss: Research Institute of Pharmaceutical Sciences, School of Pharmacy, University of Mississippi, National Center for the Development of Natural Products.
5. Potter DJ, Clark P, Brown MB. Potency of delta 9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology. J Forensic Sci 2008, 53:90-94. 10.1111/j.1556-4029.2007.00603.x, 18279244.
6. Substance Abuse and Mental Health Services Administration SAMHSA Office of Applied Studies: 1999-2000 National Household Survey on Drug Abuse 2001, U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration SAMHSA.
7. Hall W, Solowij N. Adverse effects of cannabis. Lancet 1998, 352:1611-1616. 10.1016/S0140-6736(98)05021-1, 9843121.
8. Kalant H. Adverse effects of cannabis on health: an update of the literature since 1996. Prog Neuropsychopharmacol Biol Psychiatry 2004, 28:849-863. 10.1016/j.pnpbp.2004.05.027, 15363608.
9. Bagoien G, Morken G, Zahlsen K, Aamo T, Spigset O. Evaluation of a urine on-site drugs of abuse screening test in patients admitted to a psychiatric emergency unit. J Clin Psychopharmacol 2009, 29:248-254. 10.1097/JCP.0b013e3181a45e78, 19440078.
10. Dennis M, Babor TF, Roebuck MC, Donaldson J. Changing the focus: the case for recognizing and treating cannabis use disorders. Addiction 2002, 97(Suppl 1):4-15.
11. Diagnostic and statistical manual of mental disorders. 1994, Washington DC: American Psychiatric Press, Association AP, 4.
12. Bachs L, Morland H. Acute cardiovascular fatalities following cannabis use. Forensic Sci Int 2001, 124:200-203. 10.1016/S0379-0738(01)00609-0, 11792512.
13. Sidney S, Beck JE, Tekawa IS, Quesenberry CP, Friedman GD. Marijuana use and mortality. Am J Public Health 1997, 87:585-590. 10.2105/AJPH.87.4.585, 1380837, 9146436.
14. Mateo I, Infante J, Gomez Beldarrain M, Garcia-Monco JC. Cannabis and cerebrovascular disease. Neurologia 2006, 21:204-208.
15. Appelboam A, Oades PJ. Coma due to cannabis toxicity in an infant. Eur J Emerg Med 2006, 13:177-179. 10.1097/01.mej.0000194405.38206.f2, 16679885.
16. Rubio F, Quintero S, Hernandez A, Fernandez S, Cozar L, Lobato IM, Pantoja S. Flumazenil for coma reversal in children after cannabis. Lancet 1993, 341:1028-1029.
17. Singh GK. Atrial fibrillation associated with marijuana use. Pediatr Cardiol 2000, 21:284. 10.1007/s002460010063, 10818197.
18. Kosior DA, Filipiak KJ, Stolarz P, Opolski G. Paroxysmal atrial fibrillation following marijuana intoxication: a two-case report of possible association. Int J Cardiol 2001, 78:183-184. 10.1016/S0167-5273(00)00459-9, 11398765.
19. Charbonney E, Sztajzel JM, Poletti PA, Rutschmann O. Paroxysmal atrial fibrillation after recreational marijuana smoking: another "holiday heart"?. Swiss Med Wkly 2005, 135:412-414.
20. Fisher BA, Ghuran A, Vadamalai V, Antonios TF. Cardiovascular complications induced by cannabis smoking: a case report and review of the literature. Emerg Med J 2005, 22:679-680. 10.1136/emj.2004.014969, 1726916, 16113206.
21. Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE. Triggering myocardial infarction by marijuana. Circulation 2001, 103:2805-2809.
22. Jones RT. Cardiovascular system effects of marijuana. J Clin Pharmacol 2002, 42:58S-63S.
23. Solowij N, Pesa N. Cognitive abnormalities and cannabis use. Rev Bras Psiquiatr 2010, 32(Suppl 1):S31-40.
24. Johns A. Psychiatric effects of cannabis. Br J Psychiatry 2001, 178:116-122. 10.1192/bjp.178.2.116, 11157424.
25. Ben Amar M, Potvin S. Cannabis and psychosis: what is the link?. J Psychoactive Drugs 2007, 39:131-142. 10.1080/02791072.2007.10399871, 17703707.
26. Lishman WA. Organic Psychiatry: The Psychological Consequences of Cerebral Disorder 1998, Oxford: Blackwell, 3.
27. Semple DM, McIntosh AM, Lawrie SM. Cannabis as a risk factor for psychosis: systematic review. J Psychopharmacol 2005, 19:187-194. 10.1177/0269881105049040, 15871146.
28. Fergusson DM, Horwood LJ, Ridder EM. Tests of causal linkages between cannabis use and psychotic symptoms. Addiction 2005, 100:354-366. 10.1111/j.1360-0443.2005.01001.x, 15733249.
29. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007, 370:319-328. 10.1016/S0140-6736(07)61162-3, 17662880.
30. Mueser KT, Yarnold PR, Rosenberg SD, Swett C, Miles KM, Hill D. Substance use disorder in hospitalized severely mentally ill psychiatric patients: prevalence, correlates, and subgroups. Schizophr Bull 2000, 26:179-192.
31. Miles H, Johnson S, Amponsah-Afuwape S, Finch E, Leese M, Thornicroft G. Characteristics of subgroups of individuals with psychotic illness and a comorbid substance use disorder. Psychiatr Serv 2003, 54:554-561. 10.1176/appi.ps.54.4.554, 12663845.
32. Brust JC. Other agents. Phencyclidine, marijuana, hallucinogens, inhalants, and anticholinergics. Neurol Clin 1993, 11:555-561.
33. Beaconsfield P, Ginsburg J, Rainsbury R. Marihuana smoking. Cardiovascular effects in man and possible mechanisms. N Engl J Med 1972, 287:209-212. 10.1056/NEJM197208032870501, 4402574.
34. Sulkowski A, Vachon L, Rich ES. Propranolol effects on acute marihuana intoxication in man. Psychopharmacology (Berl) 1977, 52:47-53.
35. Huestis MA, Boyd SJ, Heishman SJ, Preston KL, Bonnet D, Le Fur G, Gorelick DA. Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacology (Berl) 2007, 194:505-515.
36. Huestis MA, Gorelick DA, Heishman SJ, Preston KL, Nelson RA, Moolchan ET, Frank RA. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry 2001, 58:322-328. 10.1001/archpsyc.58.4.322, 11296091.
37. Wilson KC, Saukkonen JJ. Acute respiratory failure from abused substances. J Intensive Care Med 2004, 19:183-193. 10.1177/0885066604263918, 15296619.
38. Roald OK, Dahl V. Flunitrazepam intoxication in a child successfully treated with the benzodiazepine antagonist flumazenil. Crit Care Med 1989, 17:1355-1356.
39. Weinbroum A, Halpern P, Geller E. The use of flumazenil in the management of acute drug poisoning--a review. Intensive Care Med 1991, 17(Suppl 1):S32-38.
40. Lassaletta A, Martino R, Gonzalez-Santiago P, Torrijos C, Cebrero M, Garcia-Frias E. Reversal of an antihistamine-induced coma with flumazenil. Pediatr Emerg Care 2004, 20:319-320.
41. Berk M, Brook S, Trandafir AI. A comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder: a double-blind randomized controlled trial. Int Clin Psychopharmacol 1999, 14:177-180.
42. McEvoy JP, Freudenreich O, Levin ED, Rose JE. Haloperidol increases smoking in patients with schizophrenia. Psychopharmacology (Berl) 1995, 119:124-126.
43. Green AI, Noordsy DL, Brunette MF, O'Keefe C. Substance abuse and schizophrenia: pharmacotherapeutic intervention. J Subst Abuse Treat 2008, 34:61-71. 10.1016/j.jsat.2007.01.008, 2930488, 17574793.
44. Doggrell SA. Is rimonabant efficacious and safe in the treatment of obesity?. Expert Opin Pharmacother 2008, 9:2727-2731. 10.1517/14656566.9.15.2727, 18803459.
45. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl) 1982, 76:245-250.
46. Crippa JA, Zuardi AW, Hallak JE. Therapeutical use of the cannabinoids in psychiatry. Rev Bras Psiquiatr 2010, 32(Suppl 1):S56-66.
47. Zuardi AW, Crippa JA, Hallak JE, Moreira FA, Guimaraes FS. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res 2006, 39:421-429. 10.1590/S0100-879X2006000400001, 16612464.
48. Crippa JA, Zuardi AW, Garrido GE, Wichert-Ana L, Guarnieri R, Ferrari L, Azevedo-Marques PM, Hallak JE, McGuire PK, Filho Busatto G. Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology 2004, 29:417-426. 10.1038/sj.npp.1300340, 14583744.
49. Zuardi AW, Crippa JA, Hallak JE. Cannabis sativa: the plant that can induce unwanted effects and also treat them. Rev Bras Psiquiatr 2010, 32(Suppl 1):S1-2.
50. Bergamaschi MM, Queiroz RH, Chagas MH, de Oliveira DC, De Martinis BS, Kapczinski F, Quevedo J, Roesler R, Schröder N, Nardi AE, Martín-Santos R, Hallak JE, Zuardi AW, Crippa JA. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology 2011, 36:1219-1226. 10.1038/npp.2011.6, 21307846.
51. Crippa JA, Derenusson GN, Ferrari TB, Wichert-Ana L, Duran FL, Martin-Santos R, Simões MV, Bhattacharyya S, Fusar-Poli P, Atakan Z, Santos Filho A, Freitas-Ferrari MC, McGuire PK, Zuardi AW, Busatto GF, Hallak JE. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol 2011, 25:121-130. 10.1177/0269881110379283, 20829306.
52. Crippa JA, Zuardi AW, Martín-Santos R, Bhattacharyya S, Atakan Z, McGuire P, Fusar-Poli P. Cannabis and anxiety: a critical review of the evidence. Hum Psychopharmacol 2009, 24:515-523. 10.1002/hup.1048, 19693792.
53. Saito VM, Wotjak CT, Moreira FA. Pharmacological exploitation of the endocannabinoid system: new perspectives for the treatment of depression and anxiety disorders?. Rev Bras Psiquiatr 2010, 32(Suppl 1):S7-14.
54. Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, den Boer JA, Fineberg NA, Knapp M, Scott J, Wittchen HU. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2005, 19:567-596. 10.1177/0269881105059253, 16272179.
55. Budney AJ, Vandrey RG, Stanger C. Pharmacological and psychosocial interventions for cannabis use disorders. Rev Bras Psiquiatr 2010, 32(Suppl 1):S46-55.